Literature DB >> 23349304

Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.

Terry J Gaymes1, Azim M Mohamedali, Miranda Patterson, Nazia Matto, Alexander Smith, Austin Kulasekararaj, Rajani Chelliah, Nicola Curtin, Farzin Farzaneh, Sydney Shall, Ghulam J Mufti.   

Abstract

Inactivation of the DNA mismatch repair pathway manifests as microsatellite instability, an accumulation of mutations that drives carcinogenesis. Here, we determined whether microsatellite instability in acute myeloid leukemia and myelodysplastic syndrome correlated with chromosomal instability and poly (ADP-ribose) polymerase (PARP) inhibitor sensitivity through disruption of DNA repair function. Acute myeloid leukemia cell lines (n=12) and primary cell samples (n=18), and bone marrow mononuclear cells from high-risk myelodysplastic syndrome patients (n=63) were profiled for microsatellite instability using fluorescent fragment polymerase chain reaction. PARP inhibitor sensitivity was performed using cell survival, annexin V staining and cell cycle analysis. Homologous recombination was studied using immunocytochemical analysis. SNP karyotyping was used to study chromosomal instability. RNA silencing, Western blotting and gene expression analysis was used to study the functional consequences of mutations. Acute myeloid leukemia cell lines (4 of 12, 33%) and primary samples (2 of 18, 11%) exhibited microsatellite instability with mono-allelic mutations in CtIP and MRE11. These changes were associated with reduced expression of mismatch repair pathway components, MSH2, MSH6 and MLH1. Both microsatellite instability positive primary acute myeloid leukemia samples and cell lines demonstrated a downregulation of homologous recombination DNA repair conferring marked sensitivity to PARP inhibitors. Similarly, bone marrow mononuclear cells from 11 of 56 (20%) patients with de novo high-risk myelodysplastic syndrome exhibited microsatellite instability. Significantly, all 11 patients with microsatellite instability had cytogenetic abnormalities with 4 of them (36%) possessing a mono-allelic microsatellite mutation in CtIP. Furthermore, 50% reduction in CtIP expression by RNA silencing also down-regulated homologous recombination DNA repair responses conferring PARP inhibitor sensitivity, whilst CtIP differentially regulated the expression of homologous recombination modulating RecQ helicases, WRN and BLM. In conclusion, microsatellite instability dependent mutations in DNA repair genes, CtIP and MRE11 are detected in myeloid malignancies conferring hypersensitivity to PARP inhibitors. Microsatellite instability is significantly correlated with chromosomal instability in myeloid malignancies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23349304      PMCID: PMC3762096          DOI: 10.3324/haematol.2012.079251

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  37 in total

Review 1.  Defending genome integrity during DNA replication: a proposed role for RecQ family helicases.

Authors:  R K Chakraverty; I D Hickson
Journal:  Bioessays       Date:  1999-04       Impact factor: 4.345

Review 2.  Mechanisms of therapy-related carcinogenesis.

Authors:  James M Allan; Lois B Travis
Journal:  Nat Rev Cancer       Date:  2005-12       Impact factor: 60.716

3.  DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs.

Authors:  S E Fordham; E C Matheson; K Scott; J A E Irving; J M Allan
Journal:  Leukemia       Date:  2011-03-04       Impact factor: 11.528

4.  Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency.

Authors:  Phang-Lang Chen; Feng Liu; Suna Cai; Xiaoqin Lin; Aihua Li; Yumay Chen; Bingnan Gu; Eva Y-H P Lee; Wen-Hwa Lee
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

5.  BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.

Authors:  J M Hoang; P H Cottu; B Thuille; R J Salmon; G Thomas; R Hamelin
Journal:  Cancer Res       Date:  1997-01-15       Impact factor: 12.701

6.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).

Authors:  Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Hidewaki Nakagawa; Kaisa Sotamaa; Thomas W Prior; Judith Westman; Jenny Panescu; Dan Fix; Janet Lockman; Ilene Comeras; Albert de la Chapelle
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

7.  MSI-low, a real phenomenon which varies in frequency among cancer types.

Authors:  Sarah E R Halford; Elinor J Sawyer; Maryou B Lambros; Patricia Gorman; Nicola D Macdonald; Ian C Talbot; William D Foulkes; Cheryl E Gillett; Diana M Barnes; Lars A Akslen; Kwok Lee; Ian J Jacobs; Andrew M Hanby; Trivadi S Ganesan; Helga B Salvesen; Walter F Bodmer; Ian P M Tomlinson; Rebecca R Roylance
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

Review 8.  Human mismatch repair, drug-induced DNA damage, and secondary cancer.

Authors:  Peter Karran; Judith Offman; Margherita Bignami
Journal:  Biochimie       Date:  2003-11       Impact factor: 4.079

9.  PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites.

Authors:  Jean-François Haince; Darin McDonald; Amélie Rodrigue; Ugo Déry; Jean-Yves Masson; Michael J Hendzel; Guy G Poirier
Journal:  J Biol Chem       Date:  2007-11-19       Impact factor: 5.157

10.  Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.

Authors:  Azim Mohamedali; Joop Gäken; Natalie A Twine; Wendy Ingram; Nigel Westwood; Nicholas C Lea; Janet Hayden; Nora Donaldson; Carlo Aul; Norbert Gattermann; Aristotle Giagounidis; Ulrich Germing; Alan F List; Ghulam J Mufti
Journal:  Blood       Date:  2007-07-18       Impact factor: 22.113

View more
  26 in total

1.  Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.

Authors:  Gu Xiao; Devon Lundine; George K Annor; Jorge Canar; Viola Ellison; Alla Polotskaia; Patrick L Donabedian; Thomas Reiner; Galina F Khramtsova; Olufunmilayo I Olopade; Alexander Mazo; Jill Bargonetti
Journal:  Cancer Res       Date:  2019-11-27       Impact factor: 12.701

Review 2.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

Review 3.  DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.

Authors:  Maria Teresa Esposito; Chi Wai Eric So
Journal:  Chromosoma       Date:  2014-08-12       Impact factor: 4.316

Review 4.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

Review 5.  Role of PARP inhibitors in cancer biology and therapy.

Authors:  D Davar; J H Beumer; L Hamieh; H Tawbi
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  Exo1 independent DNA mismatch repair involves multiple compensatory nucleases.

Authors:  Amar Desai; Stanton Gerson
Journal:  DNA Repair (Amst)       Date:  2014-07-15

7.  PARPi potentiates with current conventional therapy in MLL leukemia.

Authors:  Lu Zhao; Chi Wai Eric So
Journal:  Cell Cycle       Date:  2017-09-08       Impact factor: 4.534

8.  Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.

Authors:  Pingping Fang; Cristabelle De Souza; Kay Minn; Jeremy Chien
Journal:  Commun Biol       Date:  2019-09-09

9.  XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Authors:  Kathleen I Pishas; Alaknanda Adwal; Susan J Neuhaus; Mark T Clayer; Gelareh Farshid; Alexander H Staudacher; David F Callen
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

10.  Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.

Authors:  Romana Koppensteiner; Eleftherios P Samartzis; Aurelia Noske; Adriana von Teichman; Ioannis Dedes; Myriam Gwerder; Patrick Imesch; Kristian Ikenberg; Holger Moch; Daniel Fink; Manuel Stucki; Konstantin J Dedes
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.